Source:http://linkedlifedata.com/resource/pubmed/id/19219016
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2009-2-16
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1552-4469
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
144-5
|
pubmed:meshHeading |
pubmed-meshheading:19219016-Antineoplastic Agents,
pubmed-meshheading:19219016-Clinical Trials as Topic,
pubmed-meshheading:19219016-Drug Delivery Systems,
pubmed-meshheading:19219016-Drug Design,
pubmed-meshheading:19219016-Humans,
pubmed-meshheading:19219016-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:19219016-Piperazines,
pubmed-meshheading:19219016-Pyrimidines
|
pubmed:year |
2009
|
pubmed:articleTitle |
A pulse at the heart of targeted therapy.
|
pubmed:publicationType |
News
|